Mounjaro®
Starting from £179.99/mo
Start journey Learn moreClinical trials behind semaglutide's licence tested it alongside a reduced-calorie diet and increased physical activity — not as a standalone treatment. So the question of what to eat on Wegovy is genuinely clinically meaningful, not just lifestyle noise. The STEP 1 trial, published in the New England Journal of Medicine, enrolled participants in a structured lifestyle programme: those assigned to semaglutide 2.4 mg lost around 15% of body weight on average over 68 weeks, but that result was achieved with dietary support, not despite the absence of it. A PDF meal plan you find through a search engine has no knowledge of your current dose, your food preferences, your medical history, or whether you're two weeks in and struggling with nausea or eight months in and eating well again. The best starting point is understanding what the evidence actually recommends — and then working from there with a clinician. Wegovy is a prescription-only medicine; a prescriber decides whether it's appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP programme's dietary component was a 500 kcal daily deficit from estimated energy needs, delivered with regular dietitian contact. That context matters when you're reading a generic PDF promising a "Wegovy meal plan", the trial didn't test the drug in isolation, and neither should you try to run it that way. NHS England's guidance on weight-management injections is explicit: wraparound support covering diet and activity is expected alongside the medicine, not a bonus feature.
What the evidence consistently points toward is not a specific branded diet but a set of principles: adequate protein at every meal to preserve lean mass while weight falls, foods with high water and fibre content to support satiety (which semaglutide is already promoting through its GLP-1 pathway), and smaller, more frequent portions during the early weeks when gastric emptying is slowest and nausea peaks. The right caloric target is personal. Population averages (around 2,000 kcal for women, 2,500 for men) are starting references, not prescriptions. Your actual needs depend on your body composition, activity level and where you are in the dose schedule.
If you want the most relevant guidance on what to eat while on Wegovy, the principles above are a reliable foundation, but a personalised plan still needs a person who knows your case.
The gastrointestinal side-effect pattern on semaglutide is fairly predictable: nausea, reflux, bloating and early fullness are most common in the first few weeks and after each dose increase, then tend to settle. During those windows, the usual advice to eat three square meals can work against you. Smaller volumes eaten slowly, with low-fat options and minimal strong smells or spice, tend to be tolerated far better than normal-sized meals that trigger a nausea wave mid-plate.
Cold or room-temperature foods often sit easier than hot ones during acute nausea phases. Fizzy drinks and alcohol add gas to an already-slowed gut. High-fat meals delay gastric emptying further, semaglutide is already doing that, so piling on a high-fat load can extend discomfort meaningfully. None of this is exotic nutritional science; it's applied common sense that generic PDFs rarely contextualise to the dose you're actually on this week.
The timing point matters more than it sounds. Someone starting treatment in January, reducing portions through February, and suddenly finding meals difficult by March (when they're three dose increases in) is in a very different position to someone six months on a stable dose eating well again. A well-structured meal plan for Wegovy needs to account for which phase you're in, not just hand you the same week-one template forever.
One consistent finding across GLP-1 weight-loss trials is that total food intake drops substantially, which is partly the point. But when overall volume falls, protein is the nutrient most likely to be shortchanged, and that matters because preserving muscle mass during active weight loss requires a consistent supply of it. Most UK dietetic guidance suggests aiming for at least 1.2 g of protein per kilogram of body weight per day during active weight loss, though your prescriber or a registered dietitian should confirm what's right for you specifically.
Micronutrient gaps are also worth taking seriously. If your appetite is significantly reduced, the variety and volume of food you're eating may not cover your full vitamin and mineral needs. Supplementation alongside Wegovy is a topic that comes up regularly in clinical consultations, it's not a fringe concern. Iron, vitamin D, B12 and calcium are the nutrients most commonly discussed, particularly for anyone already at borderline levels before starting treatment.
A downloadable PDF cannot check your blood results. It cannot ask whether you've been eating mostly plain crackers for three weeks because nothing else was tolerable. That gap is real, and it's why the clinical framing around these medicines always situates diet within supervised care rather than self-directed searching. For context on how the cost of supervised private treatment compares to navigating it alone, the Wegovy pricing page lays out what's typically included in a legitimate private service.
There's a practical answer here. The most useful thing a meal plan document can do is give you a framework to work from, rough protein targets, a list of well-tolerated foods for nausea phases, ideas for high-protein breakfasts that don't require cooking a full meal at 7am. A structured Wegovy meal plan resource built around the clinical evidence is genuinely helpful as a reference.
What it cannot replace is a clinician knowing your case. If you're already on treatment and finding the dietary side of things difficult, that conversation belongs in your aftercare, not in a PDF search at midnight. If you're considering starting and want to understand what the full package looks like (prescription, clinical oversight, dietary context and ongoing support) speaking to our prescribers is the right first step. At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, and that review covers more than just whether you meet the licence criteria.
One practical note: if you're planning to start treatment around a holiday or a busy stretch at work, it's worth timing your first pen for a week when you can pay attention to how your body responds. Payday timing, social commitments, travel plans, these are the kind of real-world details a prescriber can help you think through, and if the upfront cost is a consideration, our payment plan for Wegovy is worth looking at before you decide how to budget for treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.